



17 December 2007

Australian Stock Exchange Limited  
Exchange Centre  
20 Bridge Street  
Sydney NSW 2000

Attention: Company Announcements Office

**SHARE ISSUE**

Please find attached the following documents in relation to an issue of 743,038 ordinary shares by Advanced Nanotechnology Limited today.

These shares were issued in accordance with the Advanced Nanotechnology Limited Salary Sacrifice Share Plan approved by shareholders at the Company's Annual General Meeting held on 21 November 2007.

1. Appendix 3B – New Issue Announcement;
2. Appendix 3Y – Change of Directors Interests Notice
  - a. David Griffiths
  - b. Robert Mangioni
  - c. Bruce Cameron.

Yours sincerely

A handwritten signature in black ink that reads "D. Cesari".

Deana Cesari  
Chief Financial Officer &  
Company Secretary

ASX ANNOUNCEMENT  
 (ASX: ANO)

17 DECEMBER 2007

## APPENDIX 3B – NEW ISSUE ANNOUNCEMENT, APPLICATION FOR QUOTATION OF ADDITIONAL SECURITIES AND AGREEMENT

<b>Name of entity</b>	Advanced Nanotechnology Limited
<b>ABN</b>	54 079 845 855

We (the entity) give ASX the following information.

### PART 1 – ALL ISSUES

1	Class of securities issued or to be issued	Fully paid ordinary shares
2	Number of securities issued or to be issued (if known) or maximum number which may be issued	743,038
3	Principal terms of the securities (e.g. if options, exercise price and expiry date; if partly paid securities, the amount outstanding and due dates for payment; if convertible securities, the conversion price and dates for conversion)	Same as ordinary shares currently on issue
4	Do the securities rank equally in all respects from the date of allotment with an existing class of quoted securities?	Yes
5	Issue price or consideration	11.87 cents per ordinary share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issue of new shares in accordance with the Advanced Nanotechnology Limited Salary Sacrifice Share Plan as approved by shareholders at the Company's Annual General Meeting held on 21 November 2007

7	Dates of entering securities into uncertificated holdings or despatch of certificates	Expected to be within 5 business days
8	Number and class of all securities quoted on ASX ( <i>including</i> the securities in clause 2 if applicable)	Number – 182,150,604 Class – Fully paid ordinary shares
9	Number and class of all securities not quoted on ASX ( <i>including</i> the securities in clause 2 if applicable)	Number – 25,811,350 Class – Options to acquire fully paid ordinary shares
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	The same as previously disclosed with respect to ordinary shares on issue

## PART 2 – BONUS ISSUE OR PRO RATA ISSUE

11	Is security holder approval required?	N/a
12	Is the issue renounceable or non-renounceable?	N/a
13	Ratio in which the +securities will be offered	N/a
14	+Class of +securities to which the offer relates	N/a
15	+Record date to determine entitlements	N/a
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/a
17	Policy for deciding entitlements in relation to fractions	N/a
18	Names of countries in which the entity has +security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/a

19	Closing date for receipt of acceptances or renunciations	N/a
20	Names of any underwriters	N/a
21	Amount of any underwriting fee or commission	N/a
22	Names of any brokers to the issue	N/a
23	Fee or commission payable to the broker to the issue	N/a
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders	N/a
25	If the issue is contingent on +security holders' approval, the date of the meeting	N/a
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/a
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/a
28	Date rights trading will begin (if applicable)	N/a
29	Date rights trading will end (if applicable)	N/a
30	How do +security holders sell their entitlements in full through a broker?	N/a
31	How do +security holders sell part of their entitlements through a broker and accept for the balance?	N/a
32	How do +security holders dispose of their entitlements (except by sale through a broker)?	N/a
33	+Despatch date	N/a

**PART 3 – QUOTATION OF SECURITIES**

34	Type of securities (Tick one)	
(a)	<input checked="" type="checkbox"/>	Securities described in Part 1
(b)	<input type="checkbox"/>	All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

ENTITIES THAT HAVE TICKED BOX 34(a)

**Additional securities forming a new class of securities**

35	<input type="checkbox"/>	If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
36	<input type="checkbox"/>	If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	<input type="checkbox"/>	A copy of any trust deed for the additional +securities

ENTITIES THAT HAVE TICKED BOX 34(b)

38	Number of securities for which +quotation is sought	N/a
39	Class of +securities for which quotation is sought	N/a
40	Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?  If the additional securities do not rank equally, please state: <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	N/a

41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)	N/a	
42	Number and +class of all +securities quoted on ASX (including the securities in clause 38)	<u>Number</u> N/a	<u>+Class</u>

### QUOTATION AGREEMENT

- 1 Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX:
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
  - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
  - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: *D. Cesari*  
Company Secretary

Dated: 17 December 2007

Print Name: Deana Cesari

ASX ANNOUNCEMENT  
 (ASX: ANO)

17 DECEMBER 2007

## APPENDIX 3Y – CHANGE OF DIRECTOR’S INTEREST NOTICE

<b>Name of entity</b>	Advanced Nanotechnology Limited
<b>ABN</b>	54 079 845 855

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	David Charles Griffiths
<b>Date of last notice</b>	15 November 2006

### PART 1 – CHANGE OF DIRECTOR’S RELEVANT INTERESTS IN SECURITIES

<b>Direct or Indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b>	N/a
<b>Date of change</b>	17 December 2007
<b>No. of securities held prior to change</b>	2,200,000 fully paid ordinary shares 250,000 unlisted options to acquire ordinary fully paid shares Exercise price: 30.8 cents per ordinary share Expiry date: 21 February 2010
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	343,966 fully paid ordinary shares
<b>Number disposed</b>	Not applicable
<b>Value/Consideration</b>	11.87 cents per share
<b>No. of securities held after change</b>	2,543,966 fully paid ordinary shares 250,000 unlisted options to acquire ordinary fully paid shares
<b>Nature of change</b>	Issue of new shares in accordance with the Advanced Nanotechnology Limited Salary Sacrifice Share Plan as approved by shareholders at the Company’s Annual General Meeting held on 21 November 2007

### PART 2 – CHANGE OF DIRECTOR’S INTERESTS IN CONTRACTS

Not applicable
----------------

ASX ANNOUNCEMENT  
(ASX: ANO)

17 DECEMBER 2007

## APPENDIX 3Y – CHANGE OF DIRECTOR’S INTEREST NOTICE

<b>Name of entity</b>	Advanced Nanotechnology Limited
<b>ABN</b>	54 079 845 855

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Robert Michael Alexander Mangioni
<b>Date of last notice</b>	23 November 2006

### PART 1 – CHANGE OF DIRECTOR’S RELEVANT INTERESTS IN SECURITIES

<b>Direct or Indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b>	N/a
<b>Date of change</b>	17 December 2007
<b>No. of securities held prior to change</b>	1,600,000 fully paid ordinary shares. 250,000 unlisted options to acquire ordinary fully paid shares. Exercise price: 30.8 cents per ordinary share; Expiry date: 21 February 2010
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	216,558 fully paid ordinary shares
<b>Number disposed</b>	Not applicable
<b>Value/Consideration</b>	11.87 cents per share
<b>No. of securities held after change</b>	1,816,558 fully paid ordinary shares 250,000 unlisted options to acquire ordinary fully paid shares
<b>Nature of change</b>	Issue of new shares in accordance with the Advanced Nanotechnology Limited Salary Sacrifice Share Plan as approved by shareholders at the Company’s Annual General Meeting held on 21 November 2007

### PART 2 – CHANGE OF DIRECTOR’S INTERESTS IN CONTRACTS

Not applicable
----------------

ASX ANNOUNCEMENT  
(ASX: ANO)

17 DECEMBER 2007

## APPENDIX 3Y – CHANGE OF DIRECTOR’S INTEREST NOTICE

<b>Name of entity</b>	Advanced Nanotechnology Limited
<b>ABN</b>	54 079 845 855

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Bruce Cameron
<b>Date of last notice</b>	27 November 2007

### PART 1 – CHANGE OF DIRECTOR’S RELEVANT INTERESTS IN SECURITIES

<b>Direct or Indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b>	N/a
<b>Date of change</b>	17 December 2007
<b>No. of securities held prior to change</b>	700,000 fully paid ordinary shares 250,000 unlisted options to acquire fully paid ordinary shares Exercise price: 30.8 cents per ordinary share Expiry date: 21 February 2010
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	174,089 fully paid ordinary shares
<b>Number disposed</b>	Not applicable
<b>Value/Consideration</b>	11.87 cents per share
<b>No. of securities held after change</b>	874,089 fully paid ordinary shares 250,000 unlisted options to acquire fully paid ordinary shares
<b>Nature of change</b>	Issue of new shares in accordance with the Advanced Nanotechnology Limited Salary Sacrifice Share Plan as approved by shareholders at the Company’s Annual General Meeting held on 21 November 2007

### PART 2 – CHANGE OF DIRECTOR’S INTERESTS IN CONTRACTS

Not applicable
----------------